We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Partnership to Develop and Deliver Solutions for Interpreting Diagnostic Tests

By LabMedica International staff writers
Posted on 08 Oct 2012
Ingenuity Systems (Redwood City, CA, USA) has announced a partnership with Life Technologies Corporation (Carlsbad, CA, USA) to develop and deliver a joint solution for rapid, high-confidence interpretation of molecular profiling information from Life Technologies' molecular diagnostic tests.

Ingenuity Systems’ unique software and content will be provided to interpreting physicians, such as molecular pathologists and medical geneticists, in a dedicated portal, which will initially be made available for Life Technologies' emerging line of cancer diagnostic tests. More...
Users of this interpretation portal will be able to review disease management guidelines, identify clinical trials, and find cutting-edge insights from biomedical research. The Ingenuity Systems solution will be made available in context with other software and database solutions to provide a wide range of information. Interpreting physicians will leverage the comprehensive, expert-curated “Ingenuity Knowledge Base” of biomedical content. Results of the interpretation process will then be conveyed through a reporting portal to treating physicians. While these tools will not provide medical decisions to treating physicians, they will provide contextual information that could often help identify suitable treatment options based on biological factors of an individual patient's disease.

"Advanced diagnostic tests [...] will deliver increasingly complex information about a patient's disease. It is essential that those results be made relevant to interpreting physicians by making all possible contextual information available in a single interpretation portal. We believe that Ingenuity Systems provides unique and valuable information, and we are pleased to work with them to shape the repertoire of information that the physicians interpreting our tests can employ to understand the biology of their patient's disease," said Ronnie Andrews, president, Life Technologies’ Medical Sciences division.

"With its broad technology platforms and targeted acquisitions Life Technologies is rapidly emerging as a leading provider of clinical diagnostic solutions," said Jake Leschly, CEO, Ingenuity Systems; "Our unique content and applications address a critical bottleneck in the development of the clinical diagnostic market and our partnership with [Life Technologies] enables a unique and powerful end-to-end solution for the molecular pathologist."

Related Links:
Ingenuity Systems
Life Technologies


Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automatic Hematology Analyzer
DH-800 Series
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Whole-genome sequencing enables broader detection of DNA repair defects to guide PARP inhibitor cancer therapy (Photo courtesy of Illumina)

Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment

Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more

Pathology

view channel
Image: AI models combined with DOCI can classify thyroid cancer subtypes (Photo courtesy of T. Vasse et al., doi 10.1117/1.BIOS.3.1.015001)

AI-Powered Label-Free Optical Imaging Accurately Identifies Thyroid Cancer During Surgery

Thyroid cancer is the most common endocrine cancer, and its rising detection rates have increased the number of patients undergoing surgery. During tumor removal, surgeons often face uncertainty in distinguishing... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.